Impax Labs (IPXL) licenses exclusive US commercialization to Zomig from AstraZeneca (AZN)
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Join SI Premium – FREE
Impax Labs (Nasdaq: IPXL) licenses exclusive US commercialization to Zomig from AstraZeneca (NYSE: AZN). The company will pay $130 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca's Tezspire meets endpoints in esophagitis trial
- Einride launches Flip AI for electric fleet and charging operations
- Paul Cappuccio resigns from Rumble board to join Reddit
Create E-mail Alert Related Categories
Corporate News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
